Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
U.S. stock futures climbed in early trading as reports of U.S.-Iran peace talks and a rebound in technology names supported markets. Intel and Navan posted notable premarket gains after analyst upgrades and better-than-expected quarterly results, respectively, while Oracle declined on investor concerns about sharply higher capital spending and plan…
A Bloomberg Z-score assessment of U.S. dollar-denominated investment grade technology debt shows select IBM and Dell bonds trading significantly tighter than their peer group averages, while several Broadcom-related securities displayed unusually wide spreads. The analysis highlights relative spread moves in primary tech issuers including Qualcomm …
Glenn W. Stetson, Matador Resources Co (NYSE:MTDR) Executive Vice President and Chief Operating Officer, has executed a direct equity purchase, acquiring 500 shares at $53.41 per share, totaling $26,705. This transaction occurs as the company's stock has appreciated 31% year-to-date, currently trading near $54.91. Analysts suggest the stock may be …
GoGold (GLGDF) is a sub-$1B gold developer/producer with near-term production, a deep exploration pipeline and rising market interest in permitted projects. With a market cap of ~$943M, modest valuation multiples and growing short interest, the stock looks set up for a mid-term swing if a handful of permit and production catalysts arrive. Trade pla…
Kazakhstan will raise its national minimum monthly wage in 2027, with the government to decide the exact increase after August 1. The current floor is 85,000 tenge (about $174) and was left unchanged for 2026. Officials are also weighing pay rises for government and other workers, while the central bank says the move is unlikely to materially boost…
Matador Resources Co (NYSE:MTDR) Chairman and CEO Joseph Wm Foran executed a strategic purchase of company shares, reflecting continued executive confidence in the firm's operational trajectory and valuation prospects. The acquisition underscores internal alignment with shareholder interests as the energy company navigates recent financial results …
Turkey's central bank left its policy rate unchanged at 37% on Thursday, the third straight meeting with no change, and kept the overnight lending rate at 40% and borrowing rate at 35.5%. The bank said it would continue to monitor inflationary effects from the Iran conflict after raising its end-2026 interim inflation target in May and noting prono…
Facing insufficient parliamentary backing, Sweden's government has dropped a proposal to house violent offenders as young as 13 in special prison units. Justice Minister Gunnar Strommer said the administration will instead prepare legislation to reduce the age of criminal responsibility from 15 to 14, part of measures aimed at addressing a surge in…
ResMed is trading below its shorter-term moving averages after a recent pullback, but the fundamental case remains intact: diversified revenue streams, double-digit top-line growth, and strong free cash flow. The risk that GLP-1 weight-loss drugs will materially shrink ResMed's addressable market is overstated. Enter a mid-term long with a tight st…
Syndax Pharmaceuticals reported robust clinical activity of its FDA-approved menin inhibitor, Revuforj (revumenib), presented at EHA 2026. Data from real-world studies, phase 1 and 2 trials indicate high response rates and durable remissions in relapsed/refractory and newly diagnosed patients with NPM1-mutated, KMT2A-rearranged, and NUP98-rearrange…
Oppenheimer raised its Tesla fiscal estimates in light of a SpaceX IPO but pushed back against investor chatter about a merger, arguing that two independent public companies provide the capital flexibility CEO Elon Musk needs to pursue AI ambitions. The firm raised revenue and EPS forecasts for 2026 and lifted vehicle and energy storage sales proje…
Kyivstar Group Ltd., a Nasdaq-listed Ukrainian digital operator, announced that its ride-hailing service Uklon has launched "Uklon Store," an in-app marketplace initially offering flower delivery in Kyiv. This marks Uklon's first expansion beyond mobility services into everyday commerce, leveraging Uklon's 5.1 million active users and delivery netw…
Medifast Inc. emphasizes the unique metabolic challenges women face during perimenopause and menopause, promoting its OPTAVIA weight management program designed specifically to reduce visceral fat while preserving lean muscle. The company backs its approach with clinical research highlighting significant fat loss and muscle retention when compared …
Medifast, trading under NYSE: MED, emphasizes the scientific rigor behind its OPTAVIA weight loss program, which is backed by randomized controlled trials using clinical gold-standard DXA scanning to track body composition changes. The company highlights strong weight loss outcomes, high study completion rates, and significant fat loss with lean ma…
Kyivstar Group Ltd., a Nasdaq-listed Ukrainian digital operator, announced that its subsidiary Uklon has launched Uklon Store, an in-app marketplace starting with a Flowers category in Kyiv. This strategic move aims to accelerate ecosystem monetization by leveraging Uklon's ride-hailing infrastructure to enter e-commerce, increase user engagement, …
Relmada Therapeutics appointed Michael Quirk, PhD, a CNS drug development expert, as Senior Advisor for its sepranolone program targeting Prader-Willi Syndrome and other CNS disorders. Dr. Quirk's extensive experience in neuroactive steroid biology and translational neuroscience is expected to advance clinical development of sepranolone, a GABAA re…
The Lovesac Company reported its first quarter fiscal 2027 results with net sales largely flat compared to the prior year, driven by showroom expansion offset by shop-in-shop closures. Gross profit and margin contracted due to higher transportation and tariff costs, despite price increases and cost initiatives. The company continues to advance new …
C4 Therapeutics presented Phase 1 trial results for cemsidomide, an oral IKZF1/3 degrader, showing a 53% overall response rate at the recommended Phase 2 dose in heavily pretreated relapsed/refractory multiple myeloma patients. The treatment was well tolerated with manageable side effects, supporting further development as a foundational therapy ac…
Tilray Brands' BrewDog is marking Scotland's national football team return with a limited-time promotion that rolls pint prices back to £2 at Scottish BrewDog bars for a 72-hour weekend and launches a £19.98 online beer bundle. This campaign aims to increase footfall, celebrate local heritage, and expand e-commerce sales, supporting BrewDog's broad…
Tonix Pharmaceuticals Holding Corp., a US-listed biotechnology company specializing in CNS and immunology treatments, announced its executive team's participation in BTIG Infectious Disease Day 2026, held virtually on June 16, 2026. The company focuses on commercial-stage products for fibromyalgia and migraines, while advancing a pipeline addressin…
Aqua Metals, Inc. has been selected as the industrial partner in a DOE-funded program led by Idaho National Laboratory to develop electrochemical methods for refining nickel and cobalt from lithium-ion battery recycling streams. This collaboration leverages Aqua Metals' pilot facilities and expertise to enhance domestic critical minerals refining t…
Climb Bio announced initial Phase 1b clinical data demonstrating that Budoprutug, an anti-CD19 monoclonal antibody, exhibits an encouraging safety profile, robust B-cell depletion, and meaningful platelet response in heavily pretreated adult patients with primary immune thrombocytopenia (ITP). The data were presented at the European Hematology Asso…
Purple Biotech Ltd. presented new preclinical data at EACR 2026 showcasing its lead immunotherapy candidate IM1240, part of the CAPTN-3 platform. The data indicate significant improvements in pharmacokinetics, safety, and anti-tumor efficacy, particularly in immunotherapy-resistant cancers such as head and neck, bladder, and non-small cell lung can…
Nurix Therapeutics announced updated Phase 1a/b clinical trial results for bexobrutideg (NX-5948), an oral BTK degrader, demonstrating high objective response rates and durable progression-free survival in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients, including those with prior BTK inhibitor resista…
Syndax Pharmaceuticals announced the publication and presentation of Phase 1/2 SAVE trial data evaluating an all-oral combination of Revuforj (revumenib), decitabine/cedazuridine, and venetoclax in patients with relapsed or refractory acute myeloid leukemia (AML) characterized by NPM1 mutation, KMT2A rearrangement, or NUP98 rearrangement. The trial…
